Myc Choreographs the Crosstalk Between Tumor Cells and Macrophages to Drive Immune Evasion in Cancer [electronic resource]
저자
발행사항
Ann Arbor : ProQuest Dissertations & Theses, 2022
학위수여대학
Stanford University
수여연도
2022
작성언어
영어
주제어
학위
Ph.D.
페이지수
1 online resource(212 p.)
지도교수/심사위원
Advisor: Felsher, Dean;Wang, Kevin;Oro, Anthony.
The MYC oncogene is one of the most commonly activated oncogenes in human cancer [1]. Hepatocellular carcinoma (HCC), an aggressive malignancy with prognosis, shows MYC activation in up to 70% of patients [1]. The coordinated effects of MYC on a multitude of cellular processes results in enforcement of the hallmarks of cancer. While the role of MYC in regulating cancer cell autonomous functions like cell growth, proliferation and metabolic dysfunction are well characterized [2-4], the mechanisms by which MYC modulates the host immune response are not fully understood. Macrophages are immune cells part of the mononuclear phagocyte innate immune system which play a crucial role in tumor progression and metastasis [5,6]. They are one of the largest immune populations infiltrating tumors and have a strong prognostic and therapeutic role [7]. This dissertation focuses on the mechanistic and therapeutic role of the MYC oncogene in regulating the crosstalk between liver cancer cells and macrophages.Chapter 1 of this dissertation provides a broad overview of the role of the MYC oncogene in enabling the cancer cells to evade host immune surveillance. I describe the major MYC genetic aberrations and alternate mechanisms by which the MYC-related pathways are activated in most cancers. I summarize recent studies which demonstrate how MYC signaling enables tumor cells to dysregulate their microenvironment and reprogram the host immune response. I discuss how MYC pathways not only dictate cancer cell pathophysiology but also suppress the host immune response against that cancer by promoting exclusion of surveilling lymphocytes, regulating the expression of immune checkpoints and reprogramming innate immune cells.Currently, there are very limited therapeutic options for the management of liver cancer [8]. While MYC is a prominent therapeutic target in HCC, it is generally considered undruggable. In chapter 2 I present data which establishes the therapeutic role of MYC in liver cancer. Antisense oligonucleotides (ASOs) were used to target and reduce the expression of MYC to impede tumor progression and phenotypically elicits oncogene addiction in the transgenic mouse models of MYC-driven primary hepatocellular carcinoma (HCC). I show that the ASOs effectively depleted MYC mRNA and protein expression without significant toxicity. Treatment with MYC ASO in vivo, but not with a control ASO, decreased proliferation, induced apoptosis, increased senescence, and remodeled the tumor microenvironment by recruitment of CD4+ T cells. I further demonstrate that MYC ASO inhibits the growth of human liver cancer xenografts in vivo. Thus, our results illustrate the feasibility of therapeutically targeting MYC in liver cancer.Metastasis is a major cause of mortality in cancer. In chapter 3 I demonstrate how MYC cooperates with the transcription factor Twist1 to promote metastasis in liver cancer. We generated an autochthonous transgenic mouse model whereby conditional expression of MYC and Twist1 enables hepatocellular carcinoma (HCC) to metastasize in >90% of mice. We show that MYC and Twist1 cooperate to elicit a transcriptional program associated with the expression of a cytokinome that leads to the recruitment and polarization of tumorassociated macrophages (TAM). Systemic treatment with CCL2 and IL13 induced MYCHCCs to metastasize; whereas, blockade of CCL2 and IL13 abrogated MYC/Twist1-HCC metastasis. Further, I show that MYC and TWIST1 in 33 human cancers (n=9502) predicts poor survival, CCL2/IL13 expression and TAM infiltration. Finally, I conducted a prospective clinical study to confirm that plasma levels of CCL2 and IL13 predicted invasive liver tumors. We conclude that MYC and TWIST1 cooperate to elicit crosstalk between cancer cells and macrophages to drive metastasis.The role of MYC and macrophages in determining response to immune checkpoint therapy is not fully appreciated. In chapter 4, I show MYC oncogene induces a Th2-like immune profile, with reduced CD8 T cell infiltration, activates immune checkpoint expression, and predicts responsiveness to immune checkpoint inhibition in human HCC. I confirm experimentally that MYC-driven tumors suppress pro-inflammatory antigen-presenting macrophages with increased CD40 and MHCII expression, which in turn impedes T cell response. Further, I demonstrate that the MYC-driven suppression of macrophages can be reversed by combined but not individual blockades of PDL1 and CTLA4. Moreover, depletion of macrophages abrogated the anti-neoplastic effects of PDL1 and CTLA4 blockade. Hence, I establish that MYC is a predictor of responsiveness to immunotherapy through suppression of pro-inflammatory macrophages, and this immune evasion can be overcome by combined PDL1 and CTLA4 blockade.MYC inactivation leads to reversible tumor dormancy in liver cancer [9]. The immunogenic mechanisms governing MYC-induced tumor dormancy are illustrated in chapter 5. Using transgenic mouse models of MYC driven liver cancer and human HCC therapy-resistant dormancy, I establish that the TGFβ pathway is activated in quiescent cancer stem cell-like dormant tumor cells. Single cell RNA sequencing and multiplex immunofluorescence demonstrate that immunosuppressive PDL1 expressing macrophages engulf the dormant tumor cells in the perivascular niche and secrete TGFβ1 thus enabling their survival. Lastly, I confirm that inhibition of both TGFβ and PDL1 pathways is required to eliminate dormant tumor cells and prevent cancer recurrence. I show the translational relevance of these findings using human samples therapy-resistant HCC. Thus, I have identified a novel, therapeutically vulnerable, mechanism governing macrophage-mediated dormancy in MYC-driven cancers.
분석정보
서지정보 내보내기(Export)
닫기소장기관 정보
닫기권호소장정보
닫기오류접수
닫기오류 접수 확인
닫기음성서비스 신청
닫기음성서비스 신청 확인
닫기이용약관
닫기학술연구정보서비스 이용약관 (2017년 1월 1일 ~ 현재 적용)
학술연구정보서비스(이하 RISS)는 정보주체의 자유와 권리 보호를 위해 「개인정보 보호법」 및 관계 법령이 정한 바를 준수하여, 적법하게 개인정보를 처리하고 안전하게 관리하고 있습니다. 이에 「개인정보 보호법」 제30조에 따라 정보주체에게 개인정보 처리에 관한 절차 및 기준을 안내하고, 이와 관련한 고충을 신속하고 원활하게 처리할 수 있도록 하기 위하여 다음과 같이 개인정보 처리방침을 수립·공개합니다.
주요 개인정보 처리 표시(라벨링)
목 차
3년
또는 회원탈퇴시까지5년
(「전자상거래 등에서의 소비자보호에 관한3년
(「전자상거래 등에서의 소비자보호에 관한2년
이상(개인정보보호위원회 : 개인정보의 안전성 확보조치 기준)개인정보파일의 명칭 | 운영근거 / 처리목적 | 개인정보파일에 기록되는 개인정보의 항목 | 보유기간 | |
---|---|---|---|---|
학술연구정보서비스 이용자 가입정보 파일 | 한국교육학술정보원법 | 필수 | ID, 비밀번호, 성명, 생년월일, 신분(직업구분), 이메일, 소속분야, 웹진메일 수신동의 여부 | 3년 또는 탈퇴시 |
선택 | 소속기관명, 소속도서관명, 학과/부서명, 학번/직원번호, 휴대전화, 주소 |
구분 | 담당자 | 연락처 |
---|---|---|
KERIS 개인정보 보호책임자 | 정보보호본부 김태우 | - 이메일 : lsy@keris.or.kr - 전화번호 : 053-714-0439 - 팩스번호 : 053-714-0195 |
KERIS 개인정보 보호담당자 | 개인정보보호부 이상엽 | |
RISS 개인정보 보호책임자 | 대학학술본부 장금연 | - 이메일 : giltizen@keris.or.kr - 전화번호 : 053-714-0149 - 팩스번호 : 053-714-0194 |
RISS 개인정보 보호담당자 | 학술진흥부 길원진 |
자동로그아웃 안내
닫기인증오류 안내
닫기귀하께서는 휴면계정 전환 후 1년동안 회원정보 수집 및 이용에 대한
재동의를 하지 않으신 관계로 개인정보가 삭제되었습니다.
(참조 : RISS 이용약관 및 개인정보처리방침)
신규회원으로 가입하여 이용 부탁 드리며, 추가 문의는 고객센터로 연락 바랍니다.
- 기존 아이디 재사용 불가
휴면계정 안내
RISS는 [표준개인정보 보호지침]에 따라 2년을 주기로 개인정보 수집·이용에 관하여 (재)동의를 받고 있으며, (재)동의를 하지 않을 경우, 휴면계정으로 전환됩니다.
(※ 휴면계정은 원문이용 및 복사/대출 서비스를 이용할 수 없습니다.)
휴면계정으로 전환된 후 1년간 회원정보 수집·이용에 대한 재동의를 하지 않을 경우, RISS에서 자동탈퇴 및 개인정보가 삭제처리 됩니다.
고객센터 1599-3122
ARS번호+1번(회원가입 및 정보수정)